These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2539689)

  • 21. OKT3 incubation of donor marrow for prophylaxis of acute graft-vs.-host disease (GvHD) in allogeneic bone marrow transplantation.
    Prentice HG
    J Clin Immunol; 1982 Jul; 2(3 Suppl):148S-153S. PubMed ID: 6290527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts.
    Engelhard D; Morag A; Or R; Naparstek E; Cividalli G; Ruchlemer R; Aker M; Maayan S; Slavin S
    Isr J Med Sci; 1988 Mar; 24(3):145-50. PubMed ID: 3286577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis.
    Elhasid R; Arush MB; Zaidman I; Leiba R; Barak AB; Postovsky S; Haddad N; Katz T; Pollack S; Sami I; Gidoni O; Rubin D; Mandel H; Attias D; Reisner Y; Etzioni A; Rowe JM
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):329-38. PubMed ID: 17317586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
    Juckett M; Rowlings P; Hessner M; Keever-Taylor C; Burns W; Camitta B; Casper J; Drobyski WR; Hanson G; Horowitz M; Lawton C; Margolis J; Peitryga D; Vesole D
    Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children.
    Schwinger W; Weber-Mzell D; Zois B; Rojacher T; Benesch M; Lackner H; Dornbusch HJ; Sovinz P; Moser A; Lanzer G; Schauenstein K; Ofner P; Handgretinger R; Urban C
    Br J Haematol; 2006 Oct; 135(1):76-84. PubMed ID: 16925797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic bone marrow transplantation in children at Huddinge Hospital.
    Ringdén O; Bolme P; Lönnqvist B; Tollemar J; Borgström B; Dohlhöf G; Lundgren G; Winiarski J; Gahrton G; Groth CG
    Transplant Proc; 1988 Jun; 20(3):487-90. PubMed ID: 3289190
    [No Abstract]   [Full Text] [Related]  

  • 28. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
    Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of BMT management in children and adults.
    Torlontano G; Di Girolamo G; Di Bartolomeo P; Angrilli F; Papalinetti G; Olioso P; Dragani A; Fioritoni G; Iacone A; D'Antonio D
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():59-60. PubMed ID: 2516756
    [No Abstract]   [Full Text] [Related]  

  • 30. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T-cell depletion vs unmanipulated grafts for the prevention of graft-versus-host disease.
    de Lissovoy G; Hurd D; Carter S; Beatty P; Ewell M; Henslee-Downey J; Kernan N; Yanovich S; Weisdorf D
    Bone Marrow Transplant; 2005 Sep; 36(6):539-46. PubMed ID: 16044144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interstitial pneumonia after allogeneic and autologous bone marrow transplantation.
    Funada H; Harada M; Yoshida T; Hattori K
    Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():519-30. PubMed ID: 6097710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantation.
    Würsch AM; Gratama JW; Middeldorp JM; Nissen C; Gratwohl A; Speck B; Jansen J; D'Amaro J; The TH; De Gast GC
    Clin Exp Immunol; 1985 Nov; 62(2):278-87. PubMed ID: 3002684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience.
    Bacigalupo A; Zikos P; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Mordini N; Bregante S; Berisso G; Vitale V; Sessarego M; Marmont AM
    Exp Hematol; 1998 May; 26(5):409-14. PubMed ID: 9590657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for acute graft-versus-host disease in 325 consecutive bone marrow recipients.
    Hägglund H; Boström L; Ringdén O; Nilsson B; Remberger M
    Transplant Proc; 1994 Jun; 26(3):1821-2. PubMed ID: 8030154
    [No Abstract]   [Full Text] [Related]  

  • 38. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation.
    Cornelissen JJ; Fibbe WE; Schattenberg AV; Petersen EJ; Willemze R; de Witte TJ; Löwenberg B; Verdonck LF; vd Biezen A; Brand R
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S66-70. PubMed ID: 9712499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Interstitial pneumonia in leukemia patients after allogeneic bone marrow transplantation].
    Yamauchi T; Miyamura K; Nomura S; Minami S; Yoshikawa H; Sakai S; Yoshikawa S; Kodera Y; Sao H; Tahara T
    Rinsho Ketsueki; 1986 Aug; 27(8):1361-8. PubMed ID: 3025473
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.